---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-014464"
form_type: "8-K"
ticker: "VKTX"
cik: "0001607678"
company_name: "Viking Therapeutics, Inc."
filed_at: "2025-02-05T23:59:59+00:00"
generated_at: "2026-05-27T02:42:38.864844+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Viking Therapeutics reports FY2024 net loss $110M; cash $903M; Phase 3 VK2735 planned 2Q25

## Summary
- Net loss $110.0M ($1.01 per share) for FY2024, compared to net loss $85.9M ($0.91 per share) in 2023.
- Cash, cash equivalents and short-term investments of $903M as of Dec 31, 2024, up from $362M a year earlier.
- Initiation of Phase 3 studies for subcutaneous VK2735 in obesity planned for 2Q25 after FDA End-of-Phase 2 meeting.
- Phase 2 VENTURE-Oral trial of VK2735 tablet underway in ~280 obese subjects; data expected 2H25.
- Phase 2b VOYAGE in MASH: VK2809 showed MASH resolution rates up to 75% vs 29% placebo, and fibrosis improvement.

## SEC filing metadata
- accession: 0000950170-25-014464
- form_type: 8-K
- ticker: VKTX
- cik: 0001607678
- company_name: Viking Therapeutics, Inc.
- filed_at: 2025-02-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1607678/000095017025014464/0000950170-25-014464-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1607678/000095017025014464/vktx-20250205.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-014464
- JSON: https://secwatch.observer/filing/0000950170-25-014464.json
- Plain text: https://secwatch.observer/filing/0000950170-25-014464.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.